Clarity Pharmaceuticals signs supply agreement with TerraPower for Ac-225

Clarity Pharmaceuticals (ASX: $CU6) has entered into a supply agreement with TerraPower for Ac-225, marking a significant step in the development of its first Targeted Alpha-particle Therapy (TAT) program with bisPSMA. The agreement positions Clarity to develop a best-in-class TAT 225Ac-bisPSMA product with secure supply and increased uptake and retention of bisPSMA in tumours.

Executive Commentary on Clarity's Supply Agreement and Product Development

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, expressed excitement about the potential benefits of the proprietary optimised dual-targeted PSMA product in the first TAT program utilizing TerraPower-supplied Ac-225. He highlighted the challenges in Ac-225 manufacturing and the strategic significance of securing sustainable, scalable, and environmentally preferred solutions to radionuclide sourcing. Dr. Taylor emphasized Clarity's unique position in offering powerful treatment approaches to improve outcomes for prostate cancer patients through both alpha- and beta-emitting therapies.

Summary of Clarity Pharmaceuticals' Supply Agreement and Product Development

Clarity Pharmaceuticals has signed a supply agreement with TerraPower for Ac-225, enabling the development of a best-in-class TAT 225Ac-bisPSMA product. The agreement positions Clarity to address the challenges in Ac-225 manufacturing and secure a sustainable supply chain. With a focus on 67Cu-SAR-bisPSMA and 225Ac-bisPSMA, Clarity aims to offer powerful treatment approaches to improve outcomes for prostate cancer patients. The company's strategic move to integrate TAT into its existing advanced TCT programs demonstrates its commitment to transforming cancer treatment options for adults and children.